M3, Inc. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and the Full Year Ending March 31, 2024
July 28, 2023 at 02:00 am EDT
Share
M3, Inc. provided consolidated earnings guidance for the six months ending September 30, 2023 and the full year ending March 31, 2024. For the six months ending September 30, 2023, the company expects net sales of ¥120,000 million, Operating profit of ¥32,000 million and Net profit of ¥22,200 million or ¥31.37 basic per share. The company expects profit attributable to owners of the parent company of ¥21,300 million.
For the year ending March 31, 2024, the company expects net sales of ¥250,000 million, Operating profit of ¥75,000 million and Net profit of ¥52,000 million or ¥73.65 basic per share. The company expects profit attributable to owners of the parent company of ¥50,000 million.
M3, Inc. specializes in the provision of online services dedicated to the health field. Net sales (before intra-group eliminations) break down by activity as follows:
- medical marketing support services (40.3%): services enabling doctors and health professionals to search for medical resources, use the latest medical news, exchange opinions, learn about medical products and services and career development, etc. via m3.com., MR-kun, MDLinx and MEDI: GATE;
- support services to medical institutions (16.5%):
- clinical trial related services (10.7%): clinical trial support and clinical trial operations management services;
- human resources services (6.6%);
- other (1.6%): including marketing assistance and surveys of affiliated medical companies via specialized sites.
The balance of sales (24.3%) concerns international activities.
M3, INC. 
